• Xuemei Wang, Ping Xie, Guojuan Sun, Min Zhao, Zhumei Deng, Yunxia Zhou, and Shuting Bao.
• Department of Gynecology, Hospital of Chengdu University of Traditional Chinese Medicine, College of Clinical Medicine, Chengdu University of Traditional Chinese Medicine.
• Medicine (Baltimore). 2020 Jul 24; 99 (30): e21402e21402.

BackgroundCoronavirus disease 2019 (COVID-19) is highly contagious, and the epidemic has spread to hundreds of countries around the world, and seriously threatens the life safety of people around the world. Arbidol is an antiviral drug with high potential against COVID-19, but evidence of effectiveness and safety is lacking. The systematic review protocol aims to formulate a research plan that can evaluate the efficacy and safety of arbidol for COVID-19.MethodsThe retrieval time will be from the database establishment to June 2020. The retrieval database will include the Cochrane Library, PubMed, Embase, OVID, CNKI, Wanfang, VIP, CBM, etc. The primary outcome will be clinical efficacy, and the secondary results will be accompanying symptoms, time for the temperature to return to normal, time of novel coronavirus nucleic acid turning negative, blood sample test, Computed Tomography examination, length of hospitalization, adverse reactions, and adverse events. RevManV.5.3 software will be used for meta-analysis, and fixed effects model, random-effects model, subgroup analysis, and descriptive analysis will be adopted according to the heterogeneity of the research results.ResultsTo provide the latest evidence of clinical efficacy and safety of arbidol in the treatment of COVID-19.ConclusionOur study will provide the latest evidence analysis of the efficacy and safety of arbidol for COVID-19, to provide evidence-based medicine for the prevention and control of this epidemic.Registration DetailsPROSPERO CRD42020189203.

32 keywords...

hide…